

SPECIALTY GUIDELINE MANAGEMENT

TAKHZYRO (lanadelumab-flyo)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years of age and older

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

Authorization x 12 months may be granted for prevention of hereditary angioedema attacks in members 12 years of age or older when either of the following criteria is met:

- A. Member has C1 inhibitor deficiency or dysfunction as confirmed by laboratory testing.
- B. Member has normal C1 inhibitor as confirmed by laboratory testing and meets one of the following criteria:
 - 1. Member has an F12, angiopoietin-1, or plasminogen gene mutation as confirmed by genetic testing, or
 - 2. Member has a family history of angioedema and the angioedema was refractory to a trial of high-dose antihistamine (e.g., cetirizine) for at least one month.

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

IV. REFERENCES

- 1. Takhzyro [package insert]. Lexington, MA: Dyax Corp.; August 2018.
- 2. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update. *Allergy*. 2018;00:1-22.